As Filed Pursuant to Rule 424(b)(3)
                                                      Registration No. 333-37960

PROSPECTUS SUPPLEMENT
(TO PROSPECTUS DATED AUGUST 21, 2000)

                            VIROPHARMA INCORPORATED

                                 $180,000,000

                6% CONVERTIBLE SUBORDINATED NOTES DUE 2007 AND
            THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES

     This prospectus supplement relates to the resale by holders of our 6%
convertible subordinated notes due March 1, 2007 and the shares of common stock
issuable upon the conversion of the notes.  This prospectus supplement should be
read in conjunction with the prospectus dated August 21, 2000 which is to be
delivered with this prospectus supplement.

     The information appearing in the table below, as of the date hereof,
supplements and supersedes in part the information in the table appearing under
the heading "Selling Securityholders" in the prospectus:




                                       Principal Amount of
                                        Notes Beneficially     Percentage of Notes    Number of Shares       Percentage of
                                            Owned and              Outstanding         of That May be        Common Stock
               Name                       Offered Hereby                                   Sold(1)            Outstanding
                                                                                                     
Winchester Convertible Plus Ltd.               $350,000                  *                   3,206                  *
San Diego County Employee's                    $ 70,000                  *                     641                  *
 Retirement Association
IBM Retirement Plan - High Income              $105,000                  *                     961                  *
Museum of Fine Arts, Boston                    $ 20,000                  *                     183                  *
University of Rochester                        $ 20,000                  *                     183                  *
Parker-Hannifin Corporation                    $ 40,000                  *                     366                  *
Putnam Convertible Income-Growth               $480,000                  *                   4,397                  *
 Trust
Putnam Convertible Opportunities               $ 50,000                  *                     458                  *
 and Income Trust
Putnam Asset Allocation                        $120,000                  *                   1,099                  *
 Funds-Balanced Portfolio
Putnam Asset Allocation                        $ 80,000                  *                     732                  *
 Funds-Conservative Portfolio
Kentfield Trading, Ltd.                              --                 --                      --                 --

_____________________
*   Less than 1%.

(1) Assumes conversion of all of the holder's notes at a conversion price of
$109.15 per share of common stock. However, this conversion price will be
subject to adjustment as described under "Description of Notes--Conversion of
Notes." As a result, the amount of common stock issuable upon conversion of the
notes may increase or decrease in the future.

                                _______________

INVESTING IN THE NOTES OR THE COMMON STOCK INTO WHICH THE NOTES ARE


CONVERTIBLE INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" BEGINNING ON PAGE
5 OF THE PROSPECTUS.

                                _______________

The Securities and Exchange Commission and state securities regulators have not
approved or disapproved these securities, or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense.



             The date of this prospectus supplement is May 9, 2001